Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Deerfield Management Trims Holding In Antares Pharma Inc (ATRS) Just Before Disastrous Setback

Page 1 of 2

According to a recent filing with the Securities and Exchange Commission, James E. Flynn‘s Deerfield Management has trimmed its stake in Antares Pharma Inc (NASDAQ:ATRS) by some 748,000 shares to a total of 20.83 million shares through three of its affiliated funds. The share price received for the transactions ranged from $2.40 to $2.48. The decreased holding still represents over 13% of Antares’ outstanding common stock.



The healthcare-focused fund Deerfield Management was launched in 1994 with $17 million in equity, which has now exceeded $5 billion. The fund invests in both public and private healthcare companies and typically has a stake in over 100 companies. At the end of the first quarter the market value of Deerfield Management’s public equity portfolio stood at $3.09 billion, up from $2.78 billion at the end of the previous quarter. Besides Antares Pharma Inc (NASDAQ:ATRS), some of the other top micro-cap health care picks of the fund include NxStage Medical, Inc. (NASDAQ:NXTM), and Avalanche Biotechnologies Inc (NASDAQ:AAVL). The fund’s top ten holdings represent more than 47% of its portfolio value and the turnover ratio for the quarter stood at 62.6%.

We don’t just track the latest moves of hedge funds. We are, in fact, more interested in their 13F filings, which we use to determine the top 15 small-cap stocks held by the funds we track. We gather and share this information based on 16 years of research which showed that these 15 most popular small-cap picks have a great potential to outperform the market, beating the S&P 500 Total Return Index by nearly one percentage point per month in backtests, and easily beating the most popular large-cap picks of funds, which nonetheless get the majority of their collective capital. Why pay fees to invest in both the best and worst ideas of a particular hedge fund when you can simply mimic only the very best ideas of the best fund managers on your own? Since the beginning of forward testing in August 2012, the Insider Monkey small-cap strategy has outperformed the market every year, returning 142%, nearly 2.5 times greater returns than the S&P 500 during the same period (see more details).

Before the current sale, Deerfield boosted its stake in Antares Pharma Inc (NASDAQ:ATRS) during May by some 9.50 million shares. So far this year the stock of the $365.74 million specialty pharmaceutical company has declined by 6.22% while the medical instruments & supplies industry has risen by 4.48% during the same time period. As for Antares Pharma Inc (ATRS)’s latest quarterly financial results, the company delivered a net loss per share of $0.05, which was off the estimated target by $0.01, while revenues of $8.3 million also fell short of estimates, by $1.02 million, though they were still 60% higher than at the end of the same quarter a year ago. Deerfield is followed by Kevin Kotler‘s Broadfin Capital and Steven Boyd‘s Armistice Capital as the second and third-largest stockholders of Avalanche Biotechnologies Inc (NASDAQ:AAVL) among the funds that we track. Their respective holdings are 4.7 million shares valued at $12.74 million and 3.8 million shares valued at $10.30 million.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!